The clinical pharmacist receives a signal when an enrolled patient is transferred. This signal is the cue for a total drug analysis of the medication therapy before and after transfer. This happens no later than 2 days after transfer. The patient?s ?home medication? is studied retrospectively. Not Applicable
Conditions
Interventions
Implementation Phase:
For each enrolled patient the drug therapy before and after each transfer will be compared and any differences will be recorded on a standard document. The following differences
Sponsors
ZNA Hospital Network Antwerp (Belgium)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Hospitalised patients above 15 years of age 2. Patients should have stayed a minimum of three days in intensive care and then undergo a transfer to a ward with surgical, medical or geriatric beds
Exclusion criteria
Exclusion criteria: Patients with a Do Not Resuscitate (DNR) code of 2 and 3 are excluded (patients where it has been agreed that certain treatments should not be started or should be withdrawn)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. These are only applicable for the intervention group 2. Determined the day after the intervention 3. Importance of the interventions are evaluated 4. The difference in outcome between the two groups will serve as a measure of the importance of a clinical pharmacist on the ward The possible primary outcome/acceptance among the intervention group is (a) implementation of the intervention or (b) no implementation. Also in the control group, the primary outcome can (a) be positive by implementing interventions or recommendations by other health care providers on their own initiative or (b) negative if no third party has intervened. | — |
Secondary
| Measure | Time frame |
|---|---|
| The degree of relevancy will be determined by an expert group: 1. Medical impact 2. Economic impact | — |
Countries
Belgium
Outcome results
None listed